Page last updated: 2024-10-30

mechlorethamine and Myelodysplastic Syndromes

mechlorethamine has been researched along with Myelodysplastic Syndromes in 12 studies

nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.

Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.

Research Excerpts

ExcerptRelevanceReference
"To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive generations of Stanford clinical trials."1.39Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. ( Advani, RH; Balise, R; Greenberg, PL; Hoppe, RT; Horning, SJ; Koontz, MZ; Rosenberg, SA, 2013)
"Risk of leukemia was 0."1.30The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con ( Anselmo, AP; Baroni, CD; Bernasconi, C; Brusamolino, E; Klersy, C; Lazzarino, M; Lunghi, F; Mandelli, F; Maurizi-Enrici, R; Orlandi, E; Pagnucco, G; Santoro, M, 1998)
"Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy."1.30High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. ( Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D, 1999)
"2) Non-Hodgkin's lymphoma has not appeared in any of the patients in this series."1.28[Second neoplasms as a late complication of the treatment of Hodgkin's disease]. ( Alvarez, A; Colomé, JA; del Potro, E; Díaz Mediavilla, J; González, FA; Martínez, R; Morales, MD; Villegas, A, 1992)
"20 untreated Hodgkin's disease patients and 1 patient relapsing after radiotherapy (17 stage IIB-IV and 4 stage I-IIA) were given doxorubicin, bleomycin, etoposide and prednisone on a 21-day cycle."1.28ABEP as primary chemotherapy for Hodgkin's disease. ( Alberto, P; Mermillod, B; Zulian, GB, 1992)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19903 (25.00)18.7374
1990's6 (50.00)18.2507
2000's2 (16.67)29.6817
2010's1 (8.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Koontz, MZ1
Horning, SJ1
Balise, R1
Greenberg, PL1
Rosenberg, SA1
Hoppe, RT1
Advani, RH1
Metayer, C1
Curtis, RE1
Vose, J2
Sobocinski, KA1
Horowitz, MM1
Bhatia, S1
Fay, JW1
Freytes, CO1
Goldstein, SC1
Herzig, RH1
Keating, A1
Miller, CB1
Nevill, TJ1
Pecora, AL1
Rizzo, JD1
Williams, SF1
Li, CY1
Travis, LB1
Weisdorf, DJ1
Kneller, A1
Cohen, N1
Berkowicz, M1
Reichart, M1
Rosner, E1
Sokolovski, M1
Nagler, A1
Rechavi, G1
Amariglio, N1
Trakhtenbrot, L1
Anderson, JR1
Kessinger, A1
Corti, C1
Theodore, C1
Bayle, C1
Rougier, P1
Nasr, F1
Cosset, JM1
Girinsky, T1
Hayat, M1
Ribrag, V1
Brusamolino, E1
Anselmo, AP1
Klersy, C1
Santoro, M1
Orlandi, E1
Pagnucco, G1
Lunghi, F1
Maurizi-Enrici, R1
Baroni, CD1
Lazzarino, M1
Mandelli, F1
Bernasconi, C1
Harrison, CN1
Gregory, W1
Hudson, GV1
Devereux, S1
Goldstone, AH1
Hancock, B1
Winfield, D1
MacMillan, AK1
Hoskin, P1
Newland, AC1
Milligan, D1
Linch, DC1
Morales, MD1
González, FA1
Villegas, A1
del Potro, E1
Díaz Mediavilla, J1
Martínez, R1
Alvarez, A1
Colomé, JA1
Zulian, GB1
Mermillod, B1
Alberto, P1
Iurlo, A1
Mecucci, C1
Van Orshoven, A1
Michaux, JL1
Boogaerts, M1
Van den Berghe, H1
Sizoo, W1
Hagenbeek, A1
Löwenberg, B1
Blayney, DW1
Longo, DL1
Young, RC1
Greene, MH1
Hubbard, SM1
Postal, MG1
Duffey, PL1
DeVita, VT1

Other Studies

12 other studies available for mechlorethamine and Myelodysplastic Syndromes

ArticleYear
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-10, Volume: 31, Issue:5

    Topics: Academic Medical Centers; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Californ

2013
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.
    Blood, 2003, Mar-01, Volume: 101, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth

2003
Acquisition of a Ph chromosome with minor BCR/ABL fusion in treatment-related myelodysplastic syndrome with chromosome 7 abnormalities in a patient treated for Hodgkin disease.
    Cancer genetics and cytogenetics, 2005, Volume: 159, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Aberrations; Chromosome

2005
Myelodysplastic syndrome after autologous transplant for lymphoma.
    Blood, 1994, Dec-01, Volume: 84, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Hodgkin Dis

1994
High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas.
    Hematological oncology, 1996, Volume: 14, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubi

1996
The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con
    Haematologica, 1998, Volume: 83, Issue:9

    Topics: Abdomen; Actuarial Analysis; Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over;

1998
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    British journal of cancer, 1999, Volume: 81, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine;

1999
[Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Sangre, 1992, Volume: 37, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom

1992
ABEP as primary chemotherapy for Hodgkin's disease.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:10

    Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabin

1992
The karyotype in secondary hematologic disorders after treatment for Hodgkin's disease. A study of 19 patients.
    Cancer genetics and cytogenetics, 1988, Volume: 36, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Hodgkin Disea

1988
[Myelodysplastic syndromes: a group of preleukemic disorders].
    Nederlands tijdschrift voor geneeskunde, 1987, Sep-19, Volume: 131, Issue:38

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia

1987
Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.
    The New England journal of medicine, 1987, Mar-19, Volume: 316, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy;

1987